Introduction
The coronavirus (COVID-19) pandemic has imposed major changes to the delivery of healthcare worldwide. In many settings, healthcare has been predominantly transitioned to telehealth (via phone or video calls), creating challenges but also unique benefits. This transition was particularly challenging for services assessing children for neurodevelopmental disorders such as autism spectrum disorder (ASD; Zwaigenbaum et al.,
2021).
To reliably diagnose ASD, one of the key areas that needs to be assessed is social communication and interaction (American Psychiatric Association,
2013). Information is often gathered through an account of an individual’s developmental history, school reports and behavioral observations. Prior to COVID-19, clinicians would often use the Autism Diagnostic Observation Schedule Second Edition (ADOS-2; Lord et al.,
2012) as an observational tool to gather information, particularly regarding social communication and interaction skills.
The ADOS-2 is a structured play-based assessment designed for face-to-face, distraction-free settings using standardised objects and toys. Clinicians must be trained in ADOS-2 administration and scoring to conduct an ADOS-2 assessment. Due to the necessity for a reliable ADOS-2 to be in-person and for items to be touched by both client and clinician, the ADOS-2 is not COVID-19 secure. Additionally, the United Kingdom (UK) government COVID-19 safety regulations and National Health Service (NHS) policies for using personal protective equipment (PPE), (especially wearing face masks), are not only far from the ADOS-2 standardised procedures, they create barriers to establishing the interpersonal context required to assess certain ASD symptoms (Berger et al.,
2022).
In response to COVID-19, the developers of the ADOS-2 created the Brief Observation of Symptoms of Autism (BOSA; Lord et al.,
2020) to ensure patients suspected of ASD could receive safe and comprehensive diagnostic assessments. The BOSA is based on standardised activities selected and adapted from two validated ASD assessment tools: the ADOS-2 (Lord et al.,
2012) and the Brief Observation of Social Communication Change (BOSCC; Grzadzinski,
2018; Grzadzinski et al.,
2016).
The social interaction activities used within the BOSA provide opportunities to create social situations in which clinicians can observe symptoms of ASD within a 12-to-14-min observation (Lord et al.,
2020). There are four separate modules of the BOSA that can be administrated depending on an individual’s age and language level. The BOSA-MV (minimally verbal) is appropriate for an individual of any age who is nonverbal or uses only single words or phrases. The BOSA-PSYF (phrase speech and young fluent) can be chosen for verbally fluent children aged six to eight. The BOSA-F1 (fluent speech F1) is designed for verbally fluent children aged between six to eight and 10 years old. The BOSA-F2 (fluent speech F2) is appropriate for verbally fluent individuals aged 11 and older, including adults. The latter two modules are very similar, except for the materials and questions being adapted to be age appropriate.
Unlike the ADOS-2, the BOSA is designed to be facilitated by any adult able to interact with a child without PPE (for example the child’s family member) to comply with COVID-19 restrictions. During the assessment, an instruction sheet is given to this adult to show them how to present and lead the child through the structured activities using the toys and objects provided. ADOS-2 trained clinicians will observe, and this can be done in a variety of ways, including through a one-way mirror in an observation room, via a video call or by being in the same room and maintaining the required social distancing and PPE. Once the BOSA is completed, the clinicians evaluate any ASD symptoms observed based on the BOSA scoring guidelines written by Lord et al., (
2020).
ASD telehealth is a rapidly evolving field, and it is important to note that at the time of writing this report, the BOSA is in the initial stages of psychometric evaluation. Dow et al. (
2021) have developed some algorithms to improve the psychometrics of the BOSA and other research may be investigating predictive effectiveness (Rynkiewicz et al.,
2020).
The BOSA is not validated yet, and so the sensitivity and specificity of the assessment is unknown, and while there are recommended cut-off scores these are preliminary at present (Dow et al.,
2021; Rynkiewicz et al.,
2020). Lord et al., (
2020) also highlight additional clinical considerations for clinicians. For example, due to the structured activities in the BOSA, certain symptoms may not be as readily apparent (e.g., restricted/repetitive behaviours and interests) as they are throughout the ADOS-2. Because of this and the brevity of the observation period there is a possible risk for “false negatives” (i.e., ruling out ASD when the person does have ASD; Lord et al.,
2020).
However, clinicians can gather a lot of information from observing interactions between a parent and child, even if this is not formally scored in the context of the BOSA activities (Lord et al.,
2020). An additional benefit of the BOSA is that it takes approximately 30 min to administer, which is significantly shorter when compared to the ADOS-2, which is often conducted over an hour-long appointment. This is a big advantage in already stretched healthcare systems where waiting lists for ASD assessments are exceeding target waiting times (NHS England,
2019; Jayanetti,
2022). Long waits for assessments are likely to cause negative diagnostic experiences, increased levels of stress and reduced levels of satisfaction in the diagnostic process (Crane et al.,
2016; Howlin & Moore,
1997; Mori et al.,
2009) as well as delaying parents and children accessing support (Mansell & Morris,
2004). Thus, if the BOSA is more time efficient and as useful for clinicians as the ADOS-2, it would be advantageous for services to consider taking forward.
Prior to the pandemic, telehealth ASD assessments had been developed and were being used, particularly for children in rural and low-socioeconomic communities who struggled to access ASD assessments (Nazneen et al.,
2015; Smith et al.,
2017). The Naturalistic Observation Diagnostic Assessment (NODA) is a store-and-forward telehealth approach to ASD diagnosis that relies on parents and care givers sharing video recordings of live events with clinicians for review and assessment. This approach enables families to record videos in their home during their day-to-day activities over several days, capturing a wider range of behaviours compared to a single clinic-based or live telehealth assessment (Smith et al.,
2017). Research has shown diagnostic decisions made after completing a NODA are similar to those made after an in-person assessment (Smith et al.,
2017).
Additionally, the Childhood Autism Rating Scale, Second Edition (CARS-2) was developed prior to the pandemic (Schopler et al.,
2010). The CARS-2 is a standardised clinician observational tool for autism symptoms in children. Clinicians complete a 15-item rating scale after observing the child’s behaviour. This is scored up and can help to identify children with autism and determine symptom severity through quantifiable ratings based on the observation and a parent interview. As with the BOSA, this can be done face-to-face or via telehealth over a videoconferencing platform (Berger et al.,
2022).
However, before COVID-19, virtual ASD assessment methods were not commonly used within the NHS. In addition to the BOSA, other telehealth ASD assessments were developed in response to the pandemic, such as the TELE-ASD-PEDS (Corona et al.,
2020). The TELE-ASD-PEDS was created to allow clinicians to remotely observe interactions (roughly lasting 15–20 min) between caregivers and their children to help with diagnostic decision-making. The tool was designed for children under 36 months of age and involves a range of eight activities designed to provide clinicians opportunities to assess any potential symptoms and behaviours related to ASD. Although there are benefits to the TELE-ASD-PEDS tool (e.g., reduced travel time and costs, familiarity of environment and people), certain limitations were noted (Wagner et al.,
2021). Technological barriers such as the difficulty of capturing certain behaviours on the camera (e.g. eye contact), unstable internet connections and lack of familiarity with the video conferencing software caused challenges for clinicians (Corona et al.,
2021; Wagner et al.,
2021). It is unclear as to whether the TELE-ASD-PEDS has been administrated in person whilst complying to COVID-19 regulations as the BOSA has, as this methodology could eliminate several technological limitations. Additionally, the age range for the TELE-ASD-PEDS is significantly smaller than that of the BOSA.
Another recently developed virtual ASD assessment tool The Adapted Virtual Autism Behavior Observation (A-VABO; Kryszak & Albright,
2020). The A-VABO invites caregivers to interact with their child by facilitating 15 activities following a script. Unlike the BOSA, the family are able to use their own toys and games, although some activities require specific items which for some families (particularly of lower socio-economic backgrounds) can become a barrier to administration (Berger et al.,
2022). Furthermore, the reading level for the A-VABO script and instructions is deemed five grades higher than that of the BOSA which again can cause challenges for facilitating caregivers and clinicians.
This paper reports on an NHS community paediatric service in England who, like many services, started using the BOSA in response to COVID-19. The BOSA was chosen due to the similarity to the ADOS-2, for which all clinicians were already trained. This also made the BOSA cost-effective for the NHS (e.g., ADOS-2 toys and games were compatible, the training and materials were free to those with prior ADOS-2 training). As some COVID-19 restrictions were being lifted, the service wanted to evaluate how useful clinicians were finding the BOSA for diagnostic decision making and whether it should continue to be used.
This project will use quantitative and qualitative data gathered within an NHS community paediatrics team. The project aims to capture clinicians’ views of using the BOSA and explore if it is useful to clarify diagnostic decisions. The results of this project will help inform services about the continued use of the BOSA.
Discussion
In response to COVID-19 and mandatory regulations, the BOSA was rapidly developed to enable ASD assessments to continue safely. Due to some COVID-19 policies still being implemented within healthcare settings, the BOSA continues to be used by clinicians. Although the BOSA has been developed based on standardised activities from two well-validated assessments (the BOSCC and ADOS-2), the BOSA has not been validated itself (and at present no empirically derived cut-offs are available), thus caution should be taken when using the BOSA as a diagnostic tool (Lord et al.,
2020; Rynkiewicz et al.,
2020).
This project aimed to evaluate clinicians’ perceptions of how helpful the BOSA is for ASD diagnostic decision making in a community paediatrics team and clinicians wider opinions on the strengths and limitations of the BOSA. Two major themes developed from data: Administration of the BOSA and the usefulness of the BOSA.
Firstly, it is important to highlight that the clinicians recruited for this study were very familiar with the ADOS-2 (half of clinicians had four or more years of experience using the ADOS-2), and were only recently asked to learn, use, and evaluate the BOSA. It is plausible that the opinions in favour of the ADOS-2 are biased due to their knowledge and expertise of using the tool. However, despite this it is worth noting that clinicians had positive reactions to aspects of the BOSA, and these findings should not be undervalued. The results are discussed to highlight useful aspects of the BOSA and what may be missing from other ASD assessment tools such as the ADOS-2. Overall, the findings show mixed attitudes towards using the BOSA. One thing that is clear, is 92% of clinicians believe a standard ADOS-2 (without face masks) is more helpful for diagnostic decision making compared to the BOSA. This was an unsurprising result due to the ADOS-2 being a validated and reliable assessment tool which all clinicians had high familiarity with. A mixed opinion was found on the usefulness of an ADOS-2 using face masks compared to a BOSA, however the three clinicians that found the BOSA to be more helpful for diagnostic decisions compared to an ADOS-2 using face masks were in the minority. It is worth noting that an ADOS-2 with face masks is not standardised nor validated, and therefore cannot be scored accurately. Although the BOSA was created to fill the gap left by not being able to carry out a valid ADOS-2, it too is not a standardised, validated ASD assessment tool. In fact, Lord et al., (
2020) encourage clinicians to rely heavily on a thorough developmental history, medical background, and parent report of symptoms due to the limitations and potential inaccuracy of the BOSA. Caution must be taken when using the BOSA to inform diagnostic decisions. Other telehealth ASD assessments which as validated may need to be considered such as the NODA or CARS-2.
When discussing the time efficiency of the BOSA, clinician opinions were mixed. The clinicians in this study highlighted that although the BOSA takes a short time to administrate, the inadequacy of the information gathered causes a greater demand on resources after the BOSA as clinicians are forced to acquire further information from other sources. This causes a delay for the children in receiving their diagnostic decision, but also increases the demand on resources in an already stretched service (NHS England,
2019). However, clinicians did acknowledge that for more straightforward cases, i.e., when a clear developmental history has been taken and ASD appears to be presenting from this, the BOSA can be more time efficient than the ADOS-2 and is helpful for confirming a diagnostic decision. If there are identifiable straightforward referrals that come into the service, completing a BOSA could speed up the diagnostic process, benefiting service resources and service users.
One of the main criticisms of the BOSA is that the brevity of the assessment reduces opportunities to observe certain behaviours and thus the likelihood for false negatives in diagnostic outcomes may be increased (Lord et al.,
2020). Of course, a false negative ASD outcome can have a detrimental impact on children. If falsely given no diagnosis, children will not receive the adequate clinical and education support they may require and place responsibility for this entirely on parents (Charman & Gotham,
2013). Moreover, these missed diagnoses may cause individuals to seek help elsewhere for their difficulties, believing they may be due to anxiety or depression and thus further increase demands on mental health services (Aggarwal & Angus,
2015). Services must take this into consideration when deciding whether to continue to use the BOSA.
Furthermore, the validity and usefulness of the BOSA for clinicians appeared to be determined by the level of parental administration. For various reasons, the parent administration of the BOSA was highlighted by many clinicians as a barrier to gathering enough information for diagnostic decisions. So much so that one clinician mentioned that at times they had to actively get involved in the BOSA due to parents struggling to administrate effectively. Inability for parents to administrate the BOSA to a high enough standard ultimately invalidates the BOSA, making it harder for clinicians to assess the child’s social skills and behaviour, and thus further assessments may need to be completed to confirm diagnostic decisions. This then delays the children and their family from receiving an outcome. The longer it takes children and their family to receive a diagnostic decision the more parental stress increases, overall dissatisfaction of the diagnostic process increases and the longer it takes for children and families to receive appropriate support (Crane et al.,
2016; Howlin & Moore,
1997; Mori et al.,
2009). Delays in diagnostic outcomes also have a detrimental impact on the service. With one assessment taking on average 15 h of professionals’ time and costing £931 (Male et al.,
2020), delays in outcomes will only take up more professionals’ time and ultimately cost the healthcare system more. This again is something to consider when services discuss the future of the BOSA or the potential use of alternative telehealth methods. Other virtual assessment tools such as the CARS-2 and TELE-ASD-PEDS are, like the BOSA, short to administrate, however the time efficiency overall when compared to the ADOS is unknown.
Some clinicians suggested the BOSA could be administrated by clinicians to address the barriers that parental administration can cause. This may increase the quality of information gathered and thus enhance the usefulness of the BOSA for diagnostic decision making. This may be an option if social distancing is no longer necessary, but some COVID-19 restrictions still apply (e.g., face masks), but if all restrictions have been lifted the standardised ADOS-2 can continue to be used.
Nevertheless, clinicians positively highlighted the opportunities that the BOSA creates to observe parent–child interaction. These observations allowed clinicians to gain insight into a wide range of parent behaviours (i.e., from high scaffolding to difficulties interacting) that could perhaps inform future support or interventions. For example, educating parents on how to adapt scaffolding in order to build their child’s social skills, or perhaps focusing on the parents’ own communication and interaction skills. Furthermore, observing parent–child interaction may be beneficial for clinicians to understand what a child finds most helpful and responds to best, to consider how this could be transferred into other settings, such as school. As well as the BOSA, other telehealth ASD assessments such as the NODA, CARS, TELE-ASD-PEDS and A-VABO also allow parent–child interactions to be observed if captured in the video content created by the family or during the videoconference. However, parent–child interaction is not something which the ADOS-2 accommodates, thus this useful information can be missed when using the assessment.
Clinicians also shared their preference for the BOSA toys and games compared to the ones used in the ADOS-2. However, some clinicians did mention the BOSA materials do not create opportunities to gather information about the children’s communication skills and understanding of social concepts, and so evidence for diagnostic decisions can be missed. This links to the potential risk of false negatives when using the BOSA (Lord et al.,
2020).
Many clinicians thought the BOSA could be advantageous in specific cases, for example, children who are selectively mute. Over 60% of children diagnosed with selective mutism also have an ASD diagnosis (Cengher et al.,
2021). In these cases, a parent administrated BOSA may allow clinicians to observe the child interact and communicate more than they would with an unfamiliar clinician during an ADOS-2.
The researchers acknowledge that this study does not come without its limitations. Firstly, the use of an online survey, as opposed to face to face or virtual interviews. Although the online survey was a more feasible method due to time restraints, it is plausible that interviewing participants would have collected more data and thus strengthened the findings of this study. Additionally, recruiting more clinicians may have improved the quality of this study. It must be noted that the conclusions of this study are based on a small number of clinicians’ opinions from a single service, and thus it is advised that future research explores this further.
Another limitation of the study is the use of two questions to ask clinicians to directly compare the usefulness of the ADOS-2 and the BOSA. In hindsight, the clinicians’ high familiarity with the ADOS-2 biases opinions when comparing it with a tool they have had minimal experience using. Furthermore, the BOSA is not yet a validated or standardised tool, thus it is inevitable that the ADOS-2 would be preferred by clinicians. Nevertheless, the finding that despite this some clinicians highlighted relative strengths of the BOSA compared to the ADOS-2 is a valuable finding.
Finally, this study did not complete any respondent validation. Again, this was not feasible due to time restraints of both researchers and clinicians. Future research should consider replicating this study in a larger service or across multiple ASD assessment services to explore clinician opinions on the BOSA further.
Conclusions
Overall, the findings highlight some useful and beneficial aspects of using the BOSA. Clinicians expressed the usefulness of observing parent–child interactions during the BOSA, something that they are unable to observe when using the ADOS-2. Clinicians also noted that the BOSA can be more beneficial for certain cases such as selective mutism due to parental administration, rather than assessments which must be administered by a trained clinician.
The clinicians in this study showed a clear preference for the familiar ADOS-2 over the BOSA, even for using face masks during an ADOS-2. Both the BOSA and ADOS-2 with face masks must be used cautiously for diagnostic decision making, and clinicians should rely more on additional information from developmental history and parent/school report of symptoms than they may have done prior to COVID-19.
Clinicians should be wary of the risks of false negatives due to the brevity of the BOSA if it continues to be used. Future use of the BOSA may be beneficial for both children and services in certain circumstances, although it is evident that the BOSA should be properly validated if services rely on it for diagnostic decisions in these cases.
This study contributes to a growing body of literature on the BOSA and alternative ASD assessments used during and after the COVID-19 pandemic.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.